13.10% of the stock of Ironwood Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health. MarketBeat has tracked 2 news articles for Ironwood Pharmaceuticals this week, compared to 1 article on an average week. Ironwood Pharmaceuticals has received a 39.23% net impact score from Upright.

The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down… The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. The volatility of IRONWOOD PHARMACEUTICALS INC’s share price is greater than that of just 5.58% US stocks with at least 200 days of trading history.

About MarketBeat

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.52% per year.

7 employees have rated Ironwood Pharmaceuticals Chief Executive Officer Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among the company’s employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

This Pharmaceutical Company Is A Better Pick Over Johnson & Johnson Stock

The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. As of 2023 March 17, Friday current price of IRWD stock is 10.480$ and our data indicates that the asset price has been in a downtrend for the past 1 year .

Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. 3 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Ironwood Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” IRWD shares.

Since then, IRWD stock has decreased by 15.7% and is now trading at $10.44. In the past three months, Ironwood Pharmaceuticals insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,412,900.00 in company stock. Ironwood Pharmaceuticals has a short interest ratio (“days to cover”) of 8.3. Let’s look at the four biotech/drug companies slated to release quarterly results on Feb 16. The supplement industry is going through a reckoning as consumers grow better informed about the products they’re willing to put into their bodies.

Dow closes down nearly 400 points Friday as bank stocks tumble

Real-time quotes, advanced visualizations, backtesting, and much more. All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.

• In 2025, IRWD is forecast to generate $235,861,810 in earnings, with the lowest earnings forecast at $235,861,810 and the highest earnings forecast at $235,861,810.
• View analysts price targets for IRWD or view top-rated stocks among Wall Street analysts.
• Ironwood Pharmaceuticals has received a consensus rating of Buy.
• Though Ironwood missed both Q4 earnings and sales estimates, the total prescription demand for the sole-marketed drug Linzess rose 9% year over year.
• WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
• This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system.

If Ironwood Pharmaceuticals takes out the full calculated possible swing range there will be an estimated 5.77% move between the lowest and the highest trading price during the day. With the FDA granting priority review to Ironwood Pharmaceuticals’ sNDA seeking label expansion of Linzess for functional constipation in kids, a decision is expected in the second quarter of 2… Ironwood reports positive top-line data from a late-stage study evaluating Linzess for functional constipation in pediatric patients aged six to 17 years.

Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy.

IRWD chart

Consensus Price Target is the stock price analysts expect to see within a period of 0-18 months. Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure. The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest.

For the United States consumer, the cost of prescription drugs is 2.56 times the cost of 32 other nations. AnaChart is not a provider of financial advice and is not an issuer of recommendations or offers to buy or sell any stock. Sign up for a Robinhood brokerage account to buy or sell IRWD stock and options commission-free. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

These returns cover a period from January 1, 1988 through February 6, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.

Bloomberg Markets The Close Romaine Bostick breaks down the day’s top stories and trading action leading into the close. For US and Canadian Stocks, the Overview page includes key statistics on the stock’s fundamentals, with a link to see more. Provides a general description of the business conducted by this company. BioCryst possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

LGND, COLL, and OMER are the stocks whose asset turnover ratios are most correlated with IRWD. Quality is the dimension where IRWD ranks best; there it ranks ahead of 99.77% of US stocks. We have 9 different ratings for every stock to help you appreciate its future potential. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.300 between high and low, or 2.94%. For the last week, the stock we are proud to introduce you to our main partner broker everfx has had daily average volatility of 2.77%. Ironwood Pharmaceuticals, Inc. is a gastrointestinal healthcare company, which is advancing the treatment of GI diseases and redefining the standard of care for GI patients.

The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Ownerin %Freefloat97.47BlackRock Fund Advisors11.80Sarissa Capital Management LP10.63Vanguard Group, Inc. 9.32Wellington Management Co. LLP8.65State Street Corp.7.25Vanguard Health Care Fund7.07iShares Core S&P Small Cap ETF6.59Westfield Capital Management Co. LP5.28LSV Asset Management5.14SPDR S&P Biotech ETF3.79Credit Suisse Capital LLC3.20BlackRock Institutional Trust Co. NA3.01Renaissance https://day-trading.info/ Technologies LLC2.84Putnam Global Health Care Fund2.69Shareholder percentage totals can add to more than 100% because some holders are included in the free float. There may be delays, omissions, or inaccuracies in the Information. The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries.